[Human pharmacokinetics of molsidomine].
Molsidomine is well absorbed by the gastro-intestinal tract and is taken up by the liver during the first passage. Its bioavailability is 60 per cent. Digestive or sublingual absorption is rapid: maximal plasma concentrations are obtained 0.5 to 1.0 hours after administration. Molsidomine is minimally bound by plasma proteins and is distributed in a volume of 1 litre/kg. The excretion is essentially extrarenal: less than 2 per cent of the administered dose is excreted in the form of unchanged molsidomine. Molsidomine is metabolized in the liver to two pharmacologically active metabolites which spontaneously and rapidly breakdown into inactive metabolites which are excreted by the kidneys. The plasma half-life of molsidomine is 1 to 2 hours: it is not modified in patients with renal failure, but it is prolonged in patients with hepatic failure. The kinetics are linear and independent of the route of administration and the dose. There is a correlation between the plasma concentration and the pharmacological effect: the minimal effective concentration is about 5 ng/ml. At the usual dose of 2 mg three times a day, there is no accumulation of the drug.
D001682:Biological Availability; D001711:Biotransformation; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007408:Intestinal Absorption; D007700:Kinetics; D008981:Molsidomine; D010069:Oxadiazoles / Q000378:metabolism*; D011485:Protein Binding; D013558:Sydnones / Q000378:metabolism*; D014018:Tissue Distribution
D010069:Oxadiazoles; D013558:Sydnones; D008981:Molsidomine
Pharmacocinétique humaine de la molsidomine.